Showing results (1-10 of 1,307) with videos related to

Sort By:
Pageof 131
The Journal of Urology|March 1, 1992
Serum prostate specific antigen as pre-screening test for prostate cancerF Labrie, A Dupont, R Suburu, et al.
British Journal of Urology|November 1, 1993
Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinomaA Dupont, L Cusan, J L Gomez, et al.
The American Journal of Medicine|May 1, 1992
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patientsJ L Gomez, A Dupont, L Cusan, et al.
The American Journal of Medicine|May 1, 1992
Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case reportJ L Gomez, A Dupont, L Cusan, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1993
Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigenF Labrie, A Dupont, R Suburu, et al.
The Journal of Urology|October 1, 1991
Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostateA Dupont, L Cusan, J L Gomez, et al.
The Journal of Urology|September 1, 1993
Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapyA Dupont, J L Gomez, L Cusan, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1993
Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancerF Labrie, A Dupont, L Cusan, et al.
Anticancer Research|March 1, 1994
Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal treatment (GnRH-A plus flutamide)M Koutsilieris, A Dupont, J Gomez, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 20, 1990
Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experienceF Labrie, A Dupont, L Cusan, et al.
Pageof 131